Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) says study results show PromarkerD is superior to the current standard of care tests for predicting future kidney function decline in type 2 diabetes
- The company says its trial of 850 patients demonstrated PromarkerD outperformed current tests in predicting the onset of diabetic kidney disease during a four year follow-up period
- During the trial, PromarkerD correctly identified 84 per cent of patients with normal kidney function who went on to experience kidney decline over the period – all of which would have been missed by the current gold standard of care
- The company is presenting its research today at the American Society of Nephrology Kidney Week 2021 conference in the US, attended by more than 10,000 people virtually
- Proteomics last traded at 98.5 cents on November 4
Proteomics International Laboratories (PIQ) announced its study results show PromarkerD is superior to the current standard of care tests for predicting future kidney function decline in type 2 diabetes.
PromarkerD is a prognostic test that can predict future kidney decline in patients with either type 2 diabetes or no existing diabetic kidney disease, using a simple blood test that measures three serum protein biomarkers.
The company said study results showed PromarkerD outperformed the current tests in predicting the onset of diabetic kidney disease during a four year follow-up period. The trial involved retrospective analysis of more than 850 patients with type 2 diabetes.
During the trial, PromarkerD correctly identified 84 per cent of patients with normal kidney function who went on to experience kidney decline over the period – all of which would have been missed by the current gold standard of care.
PromarkerD also identified 89 per cent of patients with abnormal kidney function who further declined over the course of the study.
PromarkerD gives doctors the data they need to support early introduction of preventive medications to slow the progression of diabetic kidney disease in high-risk patients, closer monitoring of risk factors in moderate-risk patients, and rationalised treatment options in low-risk patients,” Proteomics International managing director Dr Richard Lipscombe said.
The company will present its research today at the American Society of Nephrology Kidney Week 2021 conference in the US, a virtual event attracting more than 10,000 attendees.
Proteomics last traded at 98.5 cents on November 4.
